Developer docs
API playgroundTry for free, no card

Search company profiles

Abzena

Full company profile

uuid0002itd

Namestring
Abzena
Legal namestring
Abzena
Websiteurl
abzena.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Abzena is a privately held, end-to-end contract development and manufacturing organization (CDMO) plus contract research organization (CRO) specializing in complex biologics and bioconjugates. Founded in 2004 and owned by private equity firm Welsh, Carson, Anderson & Stowe, Abzena operates integrated facilities in San Diego, California (single-use cGMP biologics manufacturing, bioreactors up to 2,000L), Bristol, Pennsylvania (high-potency bioconjugation and ADC manufacturing), and Cambridge, United Kingdom (headquarters and primary R&D site at Babraham Research Campus), with a planned North Carolina GMP facility announced in conjunction with a March 2022 $65M growth round.

The company's product offering sits across two layers. The proprietary technology layer includes ThioBridge® (a site-specific ADC/AOC conjugation platform producing stable, homogeneous conjugates with controlled drug-to-antibody ratio, with two licensee candidates currently in the clinic), AbZelectPRO™ and its new AbZelectPRO™-KO and AbZelectPRO™-KO+ GS knockout cell line variants (delivering titers up to 10 g/L via Revvity's CHOSOURCE™ and ProteoNic's 2G UNic® integrations), EpiScreen® 2.0 immunogenicity testing, LabZient™ analytical data platform, Composite Human Antibody™ humanization, and Composite Proteins™ deimmunization. The service layer spans antibody discovery, antibody engineering, developability assessment, analytics and bioassays, formulation development, upstream and downstream process development, cGMP clinical through commercial manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins, plus regulatory affairs support across FDA and EMA. The company reports 1,400+ lead candidates designed, 100+ production cell lines developed, 2,000+ bioconjugates developed, 400+ ADCs produced, and 70+ integrated DNA-to-IND programs delivered.

Abzena earns revenue through three streams: fee-for-service CRO contracts (typically 12–36 month milestones), CDMO manufacturing billed per batch or campaign under long-term supply agreements, and technology licensing of proprietary platforms and antibodies (exemplified by the October 2025 exclusive commercial license of an internal mAb to Orion). Pricing is program-specific and not publicly disclosed, although AbZelectPRO™ is marketed with transparent pricing-to-IND and no royalty fees. Customer segments are horizontally oriented — emerging and established biotech and biopharma developers requiring integrated discovery, development, and manufacturing support for complex modalities — distributed across North America, Europe, and Asia-Pacific via dedicated BD professionals in each region. Repeat-client rates are described as high, with the "grow-with-the-client" strategy converting early-stage CRO programs into late-stage manufacturing supply.

Short descriptiontext

Abzena is a privately held, end-to-end biologics and bioconjugate CDMO+CRO providing integrated services from antibody discovery through cGMP manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins for biotech and pharmaceutical clients across the US and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics CDMO services, antibody drug conjugates, cell line development, bioconjugate manufacturing, contract research organization
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biologics and Bioconjugate CDMO/CRO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research & Development Services (CRO)
TypeProfessional Services
Description

Abzena provides fee-for-service contract research across discovery, antibody engineering, developability assessment, analytics, bioassays, immunogenicity testing, cell line development, and process development. Revenue is earned through milestone-based project contracts typically spanning 12–36 months for integrated programs.

abzena.com
2Contract Manufacturing Services (CDMO)
TypeManaged Services
Description

GMP clinical through commercial manufacturing of biologics and bioconjugates, including ADCs. Revenue generated through manufacturing campaigns, typically billed per batch or campaign with long-term supply agreements. Facilities in San Diego, Bristol, and Cambridge support multi-regional manufacturing.

abzena.com
3Technology Licensing
TypeLicensing Royalties
Description

Abzena licenses its proprietary platforms (ThioBridge®, AbZelectPRO™, Composite Human Antibody™, etc.) and grants exclusive commercial licenses for developed antibodies. Orion obtained an exclusive commercial license for one of Abzena's monoclonal antibodies targeting a high unmet need cancer, supporting Orion's oncology R&D pipeline.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1ThioBridge®
Description

Proprietary site-specific conjugation technology for improved ADC design and delivery

abzena.com
+5 more records
Core offering1 text field

Abzena is a fully integrated biologics and bioconjugate CDMO+CRO providing end-to-end services from antibody discovery through cGMP commercial manufacturing. Its core service portfolio spans antibody discovery, engineering, developability assessment, analytics and bioassays, immunogenicity testing, mammalian cell line development, process development, formulation, bioconjugation (ADCs, AOCs, RDCs), and clinical-to-commercial cGMP manufacturing, supported by proprietary platforms including ThioBridge®, AbZelectPRO™, EpiScreen® 2.0, LabZient™, Composite Human Antibody™, and Composite Proteins™.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Stable pools generated in 3 weeks, RCB in 10 weeks, GMP-ready in 6 months via AbZelectPRO™
+5 more records
Product overview1 text field

Abzena operates as a fully integrated biologics and bioconjugates CDMO + CRO, offering end-to-end services from antibody discovery through commercial manufacturing. The company provides a comprehensive platform of proprietary technologies including ThioBridge® for site-specific ADC/AOC conjugation, AbZelectPRO™ family of cell line development platforms (AbZelectPRO™, AbZelectPRO™-KO, AbZelectPRO™-KO+), EpiScreen® 2.0 for immunogenicity testing, LabZient™ for rapid analytical data, Composite Human Antibody™ for humanization, and Composite Proteins™ for deimmunization. These technology platforms are complemented by integrated CRO/CDMO services spanning antibody discovery, engineering, developability assessment, analytics and bioassays, cell line development, process development, formulation development, and cGMP clinical through commercial manufacturing. The company specializes in complex biologics including monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radionuclide-drug conjugates (RDCs), bispecifics, and fusion proteins, with facilities in San Diego, CA, Bristol, PA, and Cambridge, UK.

Product and service12 records
1ThioBridge® Conjugation Platform
CategoryProprietary technology platform
Description

Site-specific bioconjugation platform for ADC and AOC development, producing stable, homogeneous conjugates with precise drug-to-antibody ratio (DAR), re-bridging across disulfide bonds to create stable, scalable, high-yield conjugates for biotech and pharmaceutical developers of next-generation therapeutics.

2AbZelectPRO™ Cell Line Development Platform
CategoryCell line development platform
Description

GMP-ready, high-yielding mammalian cell line development platform using CHO-K1 expression systems with ProteoNic's 2G UNic® vector technology, enabling stable pools in 3 weeks, RCB in 10 weeks, and GMP in 6 months for biologic developers.

3AbZelectPRO™-KO GS Knockout Cell Line Platform
CategoryCell line development platform
Description

Next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression system integrated with CHOSOURCE™ cell lines for enhanced productivity and flexibility in therapeutic antibody production, available as standalone CLD or fully integrated GMP program.

4AbZelectPRO™-KO+ ADCC+ Cell Line Platform
CategoryCell line development platform
Description

Advanced GS knockout ADCC+ cell line platform (double knockout of GS and fucosyltransferase genes) for afucosylated proteins with enhanced antibody-dependent cellular cytotoxicity, available as standalone CLD or fully integrated GMP program.

5EpiScreen® 2.0 Immunogenicity Testing Platform
CategoryImmunogenicity testing platform
Description

Advanced immunogenicity risk assessment platform utilizing assays to evaluate T cell epitopes and mitigate immunogenicity risks for biologic developers.

6LabZient™ Analytical Data Platform
CategoryAnalytical data platform
Description

Rapid analytical data platform that streamlines and de-risks the path to IND applications for antibodies and biologics, enhancing operational efficiencies for biologic developers.

7Antibody Discovery Services
CategoryCRO service
Description

High-affinity antibody discovery services including hybridoma sequencing for identifying lead candidates, serving biotech and pharmaceutical companies developing therapeutic antibodies.

8Antibody Engineering Services
CategoryCRO service
Description

Antibody design, protein engineering, humanization, and deimmunization services for optimizing antibody properties, leveraging Composite Human Antibody™ and Composite Proteins™ platforms.

9Mammalian Cell Line Development Services
CategoryCDMO service
Description

GMP-ready mammalian cell line development services using CHO-K1 expression systems, accelerating timelines and ensuring scalability for biologics developers.

10cGMP Biologics Manufacturing
CategoryCDMO service
Description

Clinical through commercial cGMP manufacturing of biologics (mAbs, fusion proteins, bispecifics) with facilities in San Diego, CA and Bristol, PA, including technology transfer, scale-up, and quality systems per ICH guidelines.

11Bioconjugate Services (ADCs, AOCs, RDCs)
CategoryCDMO service
Description

Specialized bioconjugation services including linker-payload design, ADC/AOC/RDC development, complex chemistry, and GMP manufacturing for ADC, antibody-oligonucleotide conjugate, and radionuclide-drug conjugate developers.

12DNA-to-IND/CTA Integrated Program
CategoryIntegrated program
Description

Integrated accelerated pathway from DNA sequence to IND submission combining cell line development, process development, formulation, analytical methods, GMP manufacturing, and regulatory support under a single program for biotech and pharma developers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Strategic partnership to offer an integrated drug discovery and development solution, combining Mabqi's antibody discovery technology with Abzena's development and manufacturing capabilities. The collaboration leverages Mabqi's LiteMab platform and Abzena's extensive biologics services to support a broad range of modalities including monoclonal antibodies and bioconjugates, aiming to streamline and accelerate biopharma drug development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Orion obtained an exclusive commercial license for one of Abzena's monoclonal antibodies targeting a high unmet need cancer, to be used in Orion's oncology R&D pipeline. The antibody was developed at Abzena's UK facility using proprietary technology and manufacturing platforms. This collaboration supports Orion's oncology treatment development with Abzena providing ongoing manufacturing support from UK and US facilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-15
Description

Revvity licensed its proprietary CHOSOURCE™ Glutamine Synthetase (GS) knockout CHO-K1 cell lines to Abzena for integration into the AbZelectPRO™ CLD platform. CHOSOURCE™ is an industry-standard, cGMP-manufactured cell line referenced in 90+ IND filings and 4 approved drugs. The ADCC+ double knockout variant was also licensed. This partnership enables Abzena's GS knockout CLD offerings (AbZelectPRO™-KO and AbZelectPRO™-KO+).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-15
Description

ProteoNic's 2G UNic® next-generation vector technology is integrated into the AbZelectPRO™ CLD workflow, paired with Revvity's CHOSOURCE™ GS knockout cell lines. The technology boosts productivity in CHOSOURCE™ and other cell lines, enhancing Abzena's cell line development platform performance and enabling high-titer expression of up to 10g/L.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Abzena's collaboration with Argonaut Manufacturing Services Inc. was noted in the June 2024 strategic transactions in the biopharmaceutical CMO/CRO sector. Nature of collaboration relates to supply chain resilience and expanded service capabilities for biopharma customers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Contract development and manufacturing organization with dedicated ADC and bioconjugate capabilities through its Grangemouth, UK site (acquired from Coldstream). Overlaps with Abzena in ADC linker-payload synthesis and bioconjugation services, with a similar UK heritage.

TypeBroad incumbent
Description

Global biologics CDMO with extensive mammalian cell culture and microbial fermentation capabilities, plus a growing bioconjugate franchise. Comparable to Abzena in serving complex biologics developers across modalities including ADCs and bispecifics.

TypeBroad incumbent
Description

Large-scale biologics CDMO with multiple GMP plants offering end-to-end services from cell line development to commercial manufacturing. John Gill, Abzena's VP of CLD, previously worked at Samsung Biologics, indicating direct competitive overlap.

TypeBroad incumbent
Description

Global CDMO with significant biologics and bioconjugate capabilities, including the SMARTag site-specific ADC platform that directly competes with ThioBridge®. Overlaps with Abzena in ADC development, cell line services, and integrated biologics manufacturing.

TypeDirect peer
Description

Mid-to-large scale biologics CDMO offering mammalian and microbial-based therapeutic protein and bioconjugate manufacturing, including clinical and commercial GMP capacity. Most similar in scale and modality mix to Abzena among publicly tracked CDMOs.

TypeEmerging player
Description

Biotechnology company with proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform and CDMO arm, focused on novel payloads and bioconjugation technologies. Comparable to Abzena at the conjugation technology level rather than full-service CDMO scale.

TypeDirect peer
Description

Specialized bioconjugate and ADC-focused CDMO offering analytical, process development, and GMP manufacturing services. Direct comparator to Abzena for bioconjugate-focused clients with shared modality focus on ADCs and related conjugates.

TypeBroad incumbent
Description

One of the largest global biologics CDMOs operating across mammalian and microbial manufacturing, ADC payload-linker synthesis, and integrated drug substance/product services. Comparable to Abzena across biologics and bioconjugate CDMO offerings but at significantly larger scale.

TypeBroad incumbent
Description

Global CDMO with significant biologics capabilities via the Brammer Bio acquisition, providing cell line, process development, and GMP manufacturing for mAbs and ADCs. Comparable to Abzena across integrated biologics services.

TypeBroad incumbent
Description

One of the largest biologics CDMOs globally, offering cell line development, process development, and GMP manufacturing for mAbs, bispecifics, and ADCs. Compares to Abzena in integrated DNA-to-IND services and ADC manufacturing scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abzena

Biologics and Bioconjugate CDMO/CRO Servicesabzena.com

Abzena is a privately held, end-to-end biologics and bioconjugate CDMO+CRO providing integrated services from antibody discovery through cGMP manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins for biotech and pharmaceutical clients across the US and Europe.

What Abzena does

Abzena is a privately held, end-to-end contract development and manufacturing organization (CDMO) plus contract research organization (CRO) specializing in complex biologics and bioconjugates. Founded in 2004 and owned by private equity firm Welsh, Carson, Anderson & Stowe, Abzena operates integrated facilities in San Diego, California (single-use cGMP biologics manufacturing, bioreactors up to 2,000L), Bristol, Pennsylvania (high-potency bioconjugation and ADC manufacturing), and Cambridge, United Kingdom (headquarters and primary R&D site at Babraham Research Campus), with a planned North Carolina GMP facility announced in conjunction with a March 2022 $65M growth round.

The company's product offering sits across two layers. The proprietary technology layer includes ThioBridge® (a site-specific ADC/AOC conjugation platform producing stable, homogeneous conjugates with controlled drug-to-antibody ratio, with two licensee candidates currently in the clinic), AbZelectPRO™ and its new AbZelectPRO™-KO and AbZelectPRO™-KO+ GS knockout cell line variants (delivering titers up to 10 g/L via Revvity's CHOSOURCE™ and ProteoNic's 2G UNic® integrations), EpiScreen® 2.0 immunogenicity testing, LabZient™ analytical data platform, Composite Human Antibody™ humanization, and Composite Proteins™ deimmunization. The service layer spans antibody discovery, antibody engineering, developability assessment, analytics and bioassays, formulation development, upstream and downstream process development, cGMP clinical through commercial manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins, plus regulatory affairs support across FDA and EMA. The company reports 1,400+ lead candidates designed, 100+ production cell lines developed, 2,000+ bioconjugates developed, 400+ ADCs produced, and 70+ integrated DNA-to-IND programs delivered.

Abzena earns revenue through three streams: fee-for-service CRO contracts (typically 12–36 month milestones), CDMO manufacturing billed per batch or campaign under long-term supply agreements, and technology licensing of proprietary platforms and antibodies (exemplified by the October 2025 exclusive commercial license of an internal mAb to Orion). Pricing is program-specific and not publicly disclosed, although AbZelectPRO™ is marketed with transparent pricing-to-IND and no royalty fees. Customer segments are horizontally oriented — emerging and established biotech and biopharma developers requiring integrated discovery, development, and manufacturing support for complex modalities — distributed across North America, Europe, and Asia-Pacific via dedicated BD professionals in each region. Repeat-client rates are described as high, with the "grow-with-the-client" strategy converting early-stage CRO programs into late-stage manufacturing supply.

Abzena firmographics

Firmographics
Name
Abzena
Legal name
Abzena
Website
https://abzena.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Abzena is a privately held, end-to-end biologics and bioconjugate CDMO+CRO providing integrated services from antibody discovery through cGMP manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins for biotech and pharmaceutical clients across the US and Europe.
Ownership category
akta.pro rank

Abzena industry classification

Industry
Product category
Biologics and Bioconjugate CDMO/CRO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Biologics CDMO services
  • Antibody drug conjugates
  • Cell line development
  • Bioconjugate manufacturing
  • Contract research organization

Where Abzena is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Abzena business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research & Development Services (CRO): Abzena provides fee-for-service contract research across discovery, antibody engineering, developability assessment, analytics, bioassays, immunogenicity testing, cell line development, and process development. Revenue is earned through milestone-based project contracts typically spanning 12–36 months for integrated programs.
  2. Contract Manufacturing Services (CDMO): GMP clinical through commercial manufacturing of biologics and bioconjugates, including ADCs. Revenue generated through manufacturing campaigns, typically billed per batch or campaign with long-term supply agreements. Facilities in San Diego, Bristol, and Cambridge support multi-regional manufacturing.
  3. Technology Licensing: Abzena licenses its proprietary platforms (ThioBridge®, AbZelectPRO™, Composite Human Antibody™, etc.) and grants exclusive commercial licenses for developed antibodies. Orion obtained an exclusive commercial license for one of Abzena's monoclonal antibodies targeting a high unmet need cancer, supporting Orion's oncology R&D pipeline.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Abzena product offering

Product offering

Core offering

Abzena is a fully integrated biologics and bioconjugate CDMO+CRO providing end-to-end services from antibody discovery through cGMP commercial manufacturing. Its core service portfolio spans antibody discovery, engineering, developability assessment, analytics and bioassays, immunogenicity testing, mammalian cell line development, process development, formulation, bioconjugation (ADCs, AOCs, RDCs), and clinical-to-commercial cGMP manufacturing, supported by proprietary platforms including ThioBridge®, AbZelectPRO™, EpiScreen® 2.0, LabZient™, Composite Human Antibody™, and Composite Proteins™.

Product overview

Abzena operates as a fully integrated biologics and bioconjugates CDMO + CRO, offering end-to-end services from antibody discovery through commercial manufacturing. The company provides a comprehensive platform of proprietary technologies including ThioBridge® for site-specific ADC/AOC conjugation, AbZelectPRO™ family of cell line development platforms (AbZelectPRO™, AbZelectPRO™-KO, AbZelectPRO™-KO+), EpiScreen® 2.0 for immunogenicity testing, LabZient™ for rapid analytical data, Composite Human Antibody™ for humanization, and Composite Proteins™ for deimmunization. These technology platforms are complemented by integrated CRO/CDMO services spanning antibody discovery, engineering, developability assessment, analytics and bioassays, cell line development, process development, formulation development, and cGMP clinical through commercial manufacturing. The company specializes in complex biologics including monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radionuclide-drug conjugates (RDCs), bispecifics, and fusion proteins, with facilities in San Diego, CA, Bristol, PA, and Cambridge, UK.

Differentiator

Problem solved

Functional benefit

Brands

  • ThioBridge®: Proprietary site-specific conjugation technology for improved ADC design and delivery
  • AbZelectPRO™
  • EpiScreen® 2.0
  • LabZient™
  • Composite Human Antibody™
  • Composite Proteins™

Products and services

  • ThioBridge® Conjugation Platform Site-specific bioconjugation platform for ADC and AOC development, producing stable, homogeneous conjugates with precise drug-to-antibody ratio (DAR), re-bridging across disulfide bonds to create stable, scalable, high-yield conjugates for biotech and pharmaceutical developers of next-generation therapeutics.
  • AbZelectPRO™ Cell Line Development Platform GMP-ready, high-yielding mammalian cell line development platform using CHO-K1 expression systems with ProteoNic's 2G UNic® vector technology, enabling stable pools in 3 weeks, RCB in 10 weeks, and GMP in 6 months for biologic developers.
  • AbZelectPRO™-KO GS Knockout Cell Line Platform Next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression system integrated with CHOSOURCE™ cell lines for enhanced productivity and flexibility in therapeutic antibody production, available as standalone CLD or fully integrated GMP program.
  • AbZelectPRO™-KO+ ADCC+ Cell Line Platform Advanced GS knockout ADCC+ cell line platform (double knockout of GS and fucosyltransferase genes) for afucosylated proteins with enhanced antibody-dependent cellular cytotoxicity, available as standalone CLD or fully integrated GMP program.
  • EpiScreen® 2.0 Immunogenicity Testing Platform Advanced immunogenicity risk assessment platform utilizing assays to evaluate T cell epitopes and mitigate immunogenicity risks for biologic developers.
  • LabZient™ Analytical Data Platform Rapid analytical data platform that streamlines and de-risks the path to IND applications for antibodies and biologics, enhancing operational efficiencies for biologic developers.
  • Antibody Discovery Services High-affinity antibody discovery services including hybridoma sequencing for identifying lead candidates, serving biotech and pharmaceutical companies developing therapeutic antibodies.
  • Antibody Engineering Services Antibody design, protein engineering, humanization, and deimmunization services for optimizing antibody properties, leveraging Composite Human Antibody™ and Composite Proteins™ platforms.
  • Mammalian Cell Line Development Services GMP-ready mammalian cell line development services using CHO-K1 expression systems, accelerating timelines and ensuring scalability for biologics developers.
  • cGMP Biologics Manufacturing Clinical through commercial cGMP manufacturing of biologics (mAbs, fusion proteins, bispecifics) with facilities in San Diego, CA and Bristol, PA, including technology transfer, scale-up, and quality systems per ICH guidelines.
  • Bioconjugate Services (ADCs, AOCs, RDCs) Specialized bioconjugation services including linker-payload design, ADC/AOC/RDC development, complex chemistry, and GMP manufacturing for ADC, antibody-oligonucleotide conjugate, and radionuclide-drug conjugate developers.
  • DNA-to-IND/CTA Integrated Program Integrated accelerated pathway from DNA sequence to IND submission combining cell line development, process development, formulation, analytical methods, GMP manufacturing, and regulatory support under a single program for biotech and pharma developers.

Quantifiable outcome

  • Stable pools generated in 3 weeks, RCB in 10 weeks, GMP-ready in 6 months via AbZelectPRO™
  • +5 more outcomes

Companies that use Abzena

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Abzena technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Abzena partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • MabqicoreStrategic or Co-development Partner · 6 November 2025Strategic partnership to offer an integrated drug discovery and development solution, combining Mabqi's antibody discovery technology with Abzena's development and manufacturing capabilities. The collaboration leverages Mabqi's LiteMab platform and Abzena's extensive biologics services to support a broad range of modalities including monoclonal antibodies and bioconjugates, aiming to streamline and accelerate biopharma drug development.
  • Orion CorporationcoreStrategic or Co-development Partner · 23 October 2025Orion obtained an exclusive commercial license for one of Abzena's monoclonal antibodies targeting a high unmet need cancer, to be used in Orion's oncology R&D pipeline. The antibody was developed at Abzena's UK facility using proprietary technology and manufacturing platforms. This collaboration supports Orion's oncology treatment development with Abzena providing ongoing manufacturing support from UK and US facilities.
  • Revvity (CHOSOURCE™)coreTechnology or Integration · 15 September 2025Revvity licensed its proprietary CHOSOURCE™ Glutamine Synthetase (GS) knockout CHO-K1 cell lines to Abzena for integration into the AbZelectPRO™ CLD platform. CHOSOURCE™ is an industry-standard, cGMP-manufactured cell line referenced in 90+ IND filings and 4 approved drugs. The ADCC+ double knockout variant was also licensed. This partnership enables Abzena's GS knockout CLD offerings (AbZelectPRO™-KO and AbZelectPRO™-KO+).
  • ProteoNic (2G UNic®)coreTechnology or Integration · 15 September 2025ProteoNic's 2G UNic® next-generation vector technology is integrated into the AbZelectPRO™ CLD workflow, paired with Revvity's CHOSOURCE™ GS knockout cell lines. The technology boosts productivity in CHOSOURCE™ and other cell lines, enhancing Abzena's cell line development platform performance and enabling high-titer expression of up to 10g/L.
  • Argonaut Manufacturing Services Inc.minorStrategic or Co-development Partner · 1 June 2024Abzena's collaboration with Argonaut Manufacturing Services Inc. was noted in the June 2024 strategic transactions in the biopharmaceutical CMO/CRO sector. Nature of collaboration relates to supply chain resilience and expanded service capabilities for biopharma customers.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Abzena competitors and assessment

Company assessment

Direct peers

  • Piramal Pharma Solutions: Contract development and manufacturing organization with dedicated ADC and bioconjugate capabilities through its Grangemouth, UK site (acquired from Coldstream). Overlaps with Abzena in ADC linker-payload synthesis and bioconjugation services, with a similar UK heritage.
  • AGC Biologics: Mid-to-large scale biologics CDMO offering mammalian and microbial-based therapeutic protein and bioconjugate manufacturing, including clinical and commercial GMP capacity. Most similar in scale and modality mix to Abzena among publicly tracked CDMOs.
  • Bionova Scientific: Specialized bioconjugate and ADC-focused CDMO offering analytical, process development, and GMP manufacturing services. Direct comparator to Abzena for bioconjugate-focused clients with shared modality focus on ADCs and related conjugates.

Broad incumbents

  • FUJIFILM Diosynth Biotechnologies: Global biologics CDMO with extensive mammalian cell culture and microbial fermentation capabilities, plus a growing bioconjugate franchise. Comparable to Abzena in serving complex biologics developers across modalities including ADCs and bispecifics.
  • Samsung Biologics: Large-scale biologics CDMO with multiple GMP plants offering end-to-end services from cell line development to commercial manufacturing. John Gill, Abzena's VP of CLD, previously worked at Samsung Biologics, indicating direct competitive overlap.
  • Catalent (now part of Novo Holdings): Global CDMO with significant biologics and bioconjugate capabilities, including the SMARTag site-specific ADC platform that directly competes with ThioBridge®. Overlaps with Abzena in ADC development, cell line services, and integrated biologics manufacturing.
  • Lonza Biologics: One of the largest global biologics CDMOs operating across mammalian and microbial manufacturing, ADC payload-linker synthesis, and integrated drug substance/product services. Comparable to Abzena across biologics and bioconjugate CDMO offerings but at significantly larger scale.
  • Thermo Fisher Scientific (Patheon / Brammer Bio): Global CDMO with significant biologics capabilities via the Brammer Bio acquisition, providing cell line, process development, and GMP manufacturing for mAbs and ADCs. Comparable to Abzena across integrated biologics services.
  • WuXi Biologics: One of the largest biologics CDMOs globally, offering cell line development, process development, and GMP manufacturing for mAbs, bispecifics, and ADCs. Compares to Abzena in integrated DNA-to-IND services and ADC manufacturing scale.

Emerging players

  • Heidelberg Pharma: Biotechnology company with proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform and CDMO arm, focused on novel payloads and bioconjugation technologies. Comparable to Abzena at the conjugation technology level rather than full-service CDMO scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Abzena social profiles

Digital presence

Abzena financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abzena leadership team

Management profile

Number of profiles

Profiles7 records

Abzena funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abzena M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abzena

What does Abzena do?

Abzena is a fully integrated biologics and bioconjugate CDMO+CRO providing end-to-end services from antibody discovery through cGMP commercial manufacturing. Its core service portfolio spans antibody discovery, engineering, developability assessment, analytics and bioassays, immunogenicity testing, mammalian cell line development, process development, formulation, bioconjugation (ADCs, AOCs, RDCs), and clinical-to-commercial cGMP manufacturing, supported by proprietary platforms including ThioBridge®, AbZelectPRO™, EpiScreen® 2.0, LabZient™, Composite Human Antibody™, and Composite Proteins™.

Is Abzena a public or private company?

Abzena is a private company. It is classified as private equity controlled and is currently operating.

When was Abzena founded?

Abzena was founded in 2004. It employs 501 to 1,000 people.

Where is Abzena based?

Abzena is headquartered in San Diego, United States, in the North America region.

How does Abzena make money?

Three revenue lines are on record. Contract Research & Development Services (CRO) is the primary driver. The others are contract Manufacturing Services (CDMO) and technology Licensing.

Who are Abzena's main competitors?

Direct peers on record are Piramal Pharma Solutions, AGC Biologics and Bionova Scientific. Broad incumbents are FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Catalent (now part of Novo Holdings), Lonza Biologics, Thermo Fisher Scientific (Patheon / Brammer Bio) and WuXi Biologics. Heidelberg Pharma is listed as an emerging player.

Does Abzena have an API?

No public API is recorded for Abzena.

What industry is Abzena in?

Abzena's product category is Biologics and Bioconjugate CDMO/CRO Services. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsFormulation Development RoundupFour formulation development companies—Abzena, BioAgilytix, Curia Global, and Quotient Sciences—outlined their approaches to developing new drug formulations. They emphasized early risk assessment, stability studies, and demonstrating robustness across variability rather than just initial screen performance. Long-term stability data is cited as the gold standard for confirming a robust formulation.GlobeNewswireBiopharmaceutical CMO and CRO Research Report 2026: $48.79 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com released its 2026 Biopharmaceutical CMO and CRO Market Report, showing the market growing from $35.6 billion in 2025 to $38.01 billion in 2026 at a 6.8% CAGR, with projections reaching $48.79 billion by 2030 at a 6.4% CAGR. The growth is driven by increasing biologic drug development complexity, rising R&D costs, expanded clinical trial activities, and the surge in biosimilar development. Notable strategic transactions in the sector include Abzena plc. 's collaboration with Argonaut Manufacturing Services Inc. and Great Point Partners' acquisition of Lyocontract GmbH, both in June 2024, while North America remains the largest regional market and Asia-Pacific is forecast to be the fastest-growing region.YahooBiopharmaceutical CMO and CRO Research Report 2026: $48.79 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe biopharmaceutical Contract Manufacturing Organizations (CMO) and Contract Research Organizations (CRO) market is projected to grow from $38.01 billion in 2026 to $48.79 billion by 2030, driven by increasing R&D investments, demand for biologics, and rising clinical trial activities. Strategic partnerships and acquisitions are reshaping the competitive landscape, including Abzena plc. 's collaboration with Argonaut Manufacturing Services Inc. and Great Point Partners' acquisition of Lyocontract GmbH. Industry trends indicate continued outsourcing of biologic drug manufacturing and expansion of cell and gene therapy capabilities as key growth drivers through 2030.GenengnewsPrecision Engineering Defines Next-Gen ADCThe article discusses advancements in antibody-drug conjugates (ADCs) presented at the 16th Annual World ADC Conference, focusing on innovations in payload diversity, site-specific conjugation, and manufacturing strategies. It highlights the roles of Sygnature Discovery, Abzena, LOTTE Biologics, Exelixis, and Proveo in developing and optimizing ADC technologies.ContractpharmaAbzena Recognized as a Market-Leading Antibody-Drug Conjugate CDMO in Frost & Sullivan Radar ReportAbzena has been recognized as a leader in the Frost Radar™ Report for Antibody-Drug Conjugate Contract Development and Manufacturing Organizations (CDMO). Key differentiators for Abzena include its proprietary ThioBridge® platform and fully integrated service model, enhancing capabilities in the competitive CDMO landscape. This recognition emphasizes Abzena's role as a partner for complex, high-value programs in the bioconjugate sector.PR NewswireAbzena Recognized as a Market-Leading Antibody-Drug Conjugate CDMO in Frost & Sullivan Radar ReportAbzena, a contract development and manufacturing organization for complex biologics and bioconjugates, was recognized as a market leader in Frost & Sullivan's Radar Report for Antibody-Drug Conjugate CDMOs, joining 15 other companies featured in the global benchmarking analysis. Frost & Sullivan cited Abzena's proprietary ThioBridge® platform, fully integrated end-to-end service model, advanced analytical capabilities, and dual US and UK operational footprint as key differentiators. The company highlighted that its integrated facilities in San Diego, Bristol (PA), and Cambridge (UK) provide multi-regional flexibility and regulatory expertise across FDA and EMA pathways.Nova One AdvisorBiologics Contract Manufacturing Market Share Analysis Report, 2024-2033The global biologics contract manufacturing market size was USD 16.20 billion in 2023 and is projected to reach USD 52.61 billion by 2033, growing at a CAGR of 12.5%. The market is driven by increased outsourcing, advancements in biologic therapies, and expanding manufacturing capabilities in North America and Asia-Pacific. Key players include Wuxi Biologics, Abzena Ltd., FUJIFILM Diosynth Biotechnologies, and others.YahooAbzena and Mabqi partner for drug development solutionAbzena and Mabqi announced a partnership integrating antibody discovery with development and manufacturing services. The collaboration uses Mabqi's LiteMab studio for hit selection and Abzena's GMP manufacturing expertise to accelerate drug development. Both companies support modalities including monoclonal antibodies and bi-specifics.AbzenaAbzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development SolutionAbzena and Mabqi announced a strategic partnership to integrate antibody discovery with development and manufacturing services for biopharma customers. The collaboration combines Mabqi's LiteMab Antibody Discovery Studio with Abzena's capabilities in cell line development, process development, and GMP manufacturing to streamline drug development timelines.PR NewswireAbzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development SolutionAbzena and Mabqi announced a strategic partnership to combine their antibody discovery and development capabilities, aiming to provide streamlined drug development solutions for biopharma customers. The collaboration leverages Mabqi's LiteMab platform and Abzena's manufacturing expertise to support the entire process from discovery to pre-clinical development.